Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)

ClinicalTrials.gov ID: NCT07645248

Public ClinicalTrials.gov record NCT07645248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, 2-way Crossover, Multicenter Study to Evaluate the Safety of Test Propellant HFA-152a and Reference Propellant HFA-134a When Administered Via Metered Dose Inhalers

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).

Study identification

NCT ID
NCT07645248
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
110 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2026
Primary completion
Feb 24, 2027
Completion
Feb 24, 2027
Last update posted
Sep 24, 2026

2026 – 2027

United States locations

U.S. sites
11
U.S. states
7
U.S. cities
9
Facility City State ZIP Site status
GSK Investigational Site Aventura Florida 33180 Recruiting
GSK Investigational Site Miami Florida 33155 Recruiting
GSK Investigational Site Miami Florida 33173-3484 Recruiting
GSK Investigational Site Owensboro Kentucky 42301 Recruiting
GSK Investigational Site Columbia Missouri 65203 Recruiting
GSK Investigational Site Henderson Nevada 89052-5015 Recruiting
GSK Investigational Site Medford Oregon 97504 Recruiting
GSK Investigational Site Spartanburg South Carolina 29303-4225 Recruiting
GSK Investigational Site Spartanburg South Carolina 29303 Recruiting
GSK Investigational Site Cypress Texas 77429 Recruiting
GSK Investigational Site Tomball Texas 77375 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07645248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 24, 2026 · Synced Sep 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07645248 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →